|
|
Article: GlobeImmune's Series B Adds $34M For Cancer, Hepatitis C.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Yeast-based immunotherapy company GlobeImmune Inc. raised $34.3 million in its second venture financing round to fund early efficacy trials of its two lead products in cancer and hepatitis C.
The Series B was "a pretty substantial round," said Tim Rodell, CEO of GlobeImmune. "All of our Series A investors participated, and the quality of our new investors is very encouraging."
To date, the company has raised about $42 million in venture financing, plus about $4 million from an angel round and federal grant money.
The recent funding is expected to carry the company for about two years, Rodell said. "The primary milestones ...